Nictavi Partners & Eyelid Patch Market
The Tarsus Eyelid Patch addresses specific needs not met anywhere else in the market.
Vision & Eye Care Market Statistics
Estimated Total Market Size:
Our patents secure our place in the growing vision care market, which was valued in 2023 at 125 Billion dollars, and will be 192 Billion by 2026.
2015
8.22% of the population are diagnosed with eye disorders. = 3,616,800 people.
2,000,000 people are diagnosed with Amblyopia Lazy eye yearly. Eye occlusion is the common treatment for this condition.
There are 46,000 cornea transplants annually in the United States at a cost of an estimated $840,000,000. If a portion of those, and other cornea surgeries can be avoided by preventing the cornea damage, it would reduce patient’s pain, suffering, and expense, while preserving their sight.
2016
48.04% of the population are diagnosed with cataracts. = 21,000,000 people.
5.41% of the population are diagnosed with cornea disorders. = 17,690,700 people.
2.36% of the population suffer eye injuries, burns, surgical complications. = 1,038,400 people.
5.54% of the population are diagnosed with diabetic eye diseases. = 2,437,600 people.
Eye Stats: https://www.aao.org/newsroom/eye-health-statistics
Supporters & Strategic Partners
Nictavi works with and is supported by some of the top eye vision and eye care brands in the world.
CTIP: Consortium for Technology and Innovation in Pediatrics
Pediatric MedTech Accelerator
Dr. Anthony Aldave
Early Supporter
Head of the Cornea Division of the Jules Stein Eye Institute.
UCLA Jules Stein Eye Institute
100 Stein Plz, Los Angeles, CA 90095
1-310-825-5000
ScaleHealth
Early Supporter
Children’s Hospital of Los Angeles Vision Center
Small Business Development Center
SBDC At Pasadena City College, East Foothill Boulevard, Pasadena, Los Angeles, CA
Don Loewel, Albert Napoli, and Julie Zwissler
Hi-Tech Products
Contracted Manufacturer
Prototype development and manufacturing.
8530 Roland St. Buena Park, CA 90621
1-800-725-7793
Contacts: Mike Lohman, Fred Haag
USC Roski Eye Institute
Food and Drug Administration
The Tarsus Eyelid Patch Serves a Need Across the Entire Vision Care Market
Ophthalmologists and Optometrists
Used as a therapeutic to achieve more patient compliant eyelid closure for the healing corneal epithelial defects, treating Lagophthalmos, keratopathy, and after some eye surgeries, as well as a treatment for other corneal health issues.
Enhancing applicable therapies that requires eyelid closure, improving patient compliance and outcomes.
Pediatricians
To address lazy eye and other eye health issues that may be addressed by eyelid closure.
In the ICU
To achieve eyelid closure for patients in medically induced comas, as to avoid cornea damage. Due to insufficient eyelid closure corneal defects occur in 20–42% of ICU patients, and 60% of those sedated for 48 hours.
Oculoplastic Surgeons
Over-the-counter (OTC)
Hospital Groups
Distributors
Pharmaceutical companies
To accompany their eye medicines. There have been studies that show that eyelid closure enhances the delivery and increasing effectiveness of some eye medicines.
The Military – Defense Health Agency (DHA) and the VA
Anesthesiologists
Anesthesiologists
